Agilent Technologies, Inc. (A)
NYSE · Healthcare · Diagnostics & Research
$171.29+2.09%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $48.3B
- P/E (trailing)
- 33.8
- Forward P/E
- 25.4
- Dividend yield
- 0.6%
- 52-week range
- $108.35 – $177.05
- 52-week change
- +21.09%
- EPS (trailing)
- $5.07
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 25, 2026
Fiscal year to Oct 2025
- Revenue
- $6.9B (+6.73%)
- Net income
- $1.3B
- Operating margin
- 21.3%
- Diluted EPS
- $4.57
- Free cash flow
- $1.2B
From the company’s annual report on SEC EDGAR.
About Agilent Technologies, Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services.
Headquarters: Santa Clara, United States · 18,200 employees · agilent.com